- CONDITION CENTERS
The purpose of Dr. Reddy’s North American Generics operation is to provide affordable and innovative medicines for healthier lives.
Dr. Reddy’s North American Generics understands and appreciates that every “customer” of pharmaceutical products—the purchasing wholesaler/chain/retailer/ pharmacy, the prescribing physician, the patient, and the payer—has a “choice.” They have a choice of products, as well as a choice of where to acquire those products. Knowing this, we strive daily to provide the best products at the most competitive prices.
Established in 2001, Dr. Reddy’s North American Generics began marketing its finished dosage-form products in the United States and Canada. Under the Dr. Reddy’s label, the company currently markets 41 prescription products in 186 dosing presentations (i.e., strengths and package sizes). In addition, Dr. Reddy’s Private Label OTC Group, which was established in 2007, markets 7 different products in 136 packaging presentations.
Aggressive Product Pipeline
Dr. Reddy’s generic company consistently has an aggressive product pipeline—with many products under development and awaiting FDA approval. In only the past 12 months, Dr. Reddy’s has launched the following important prescription generic products: Sumatriptan (Imitrex®, Glaxo/ Smith/Kline), Divalproex (Depakote®, Abbott), Risperidone (Risperdal®, Janssen), Ramipril (Altace®, King), Venlafaxine (Effexor®, Wyeth), Lamotrigine (Lamictal®, Glaxo/Smith/ Kline), and Levetiracetam (Keppra®, UCB). We have also brought to the market generic OTC products, such as Ranitidine 150-mg tablets and Cetirizine (Zyrtec®, McNeil- PPC, Inc.) 10-mg tablets. The OTC group is also positioned uniquely to support Rx-to-OTC switches.
Dr. Reddy’s North American Generics is vertically integrated— from process development of Active Pharmaceutical Ingredients (APIs), to formulations and the submissions of ANDAs, to manufacturing of finished dosages on over 90% of our products, allowing them to compete in a marketplace that has increasing price pressure and multiple competitors.
Our modern, cutting-edge technology facilities, which have an enviable record of regulatory compliance, follow cGMP guidelines in the production of finished dosage forms.
To further expand our manufacturing capabilities, Dr. Reddy’s announced recently the acquisition of the BASF pharmaceutical contract manufacturing business, including the company’s manufacturing facility in Shreveport, Louisiana. The facility manufactures solid, semisolid, and liquid dosage forms. The future will see Dr. Reddy’s expand into additional dosage forms, including injectables, liquids, and biological, as well as topicals.
Dr. Reddy’s strives consistently to be the “first choice” for our customers, whomever they may be, by leveraging the company’s vertical integration—from the process development of APIs to finished dosage forms. The Sales, Marketing, Regulatory, Sales Operations, and Supply Chain teams at Dr. Reddy’s North American Generics possess proven expertise, and they are ready to take the company to the next level.
For more information, visit www.drreddys.com.
Dr. Reddy’s Laboratories launched the authorized generic version of Glaxo/Smith/Kline’s Imitrex® (Sumatriptan Succinate) tablets 25 mg, 50 mg, and 100 mg in November 2008.